| scholarly article | Q13442814 |
| P50 | author | Kunle Odunsi | Q38296739 |
| Christine Ambrosone | Q52931455 | ||
| P2093 | author name string | Feng Qian | |
| Shashikant Lele | |||
| Susan E McCann | |||
| William Cliby | |||
| Jonathan Tammela | |||
| Thomas Sellers | |||
| Gregory Miller | |||
| Alan Hutson | |||
| Bernadette Keitz | |||
| John P Geisler | |||
| Marilyn Intengan | |||
| James L Alderfer | |||
| Robert M Wollman | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 782-788 | |
| P577 | publication date | 2005-02-01 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics | |
| P478 | volume | 113 |
| Q34980916 | 1H NMR metabolomics study of age profiling in children |
| Q38826774 | A Pilot Study on the Utility of Serum Metabolomics in Neuroblastoma Patients and Xenograft Models |
| Q46507278 | A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy |
| Q37512830 | A review of applications of metabolomics in cancer |
| Q36603235 | Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas |
| Q26748877 | Advantages and Pitfalls of Mass Spectrometry Based Metabolome Profiling in Systems Biology |
| Q39662417 | Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases |
| Q24600728 | Applications of metabolomics in cancer research |
| Q37249682 | Applications of metabolomics in drug discovery and development |
| Q52747853 | Applying biofluid metabonomic techniques to analyze the combined subchronic toxicity of propoxur and permethrin in rats. |
| Q38244225 | Applying metabolomics to understand the aggressive phenotype and identify novel therapeutic targets in glioblastoma |
| Q35163111 | Bioinformatics tools for cancer metabolomics |
| Q35497484 | Bladder cancer determination via two urinary metabolites: a biomarker pattern approach |
| Q52560790 | Circulating MicroRNA-21 Expression as a Novel Serum Biomarker for Oral Sub-Mucous Fibrosis and Oral Squamous Cell Carcinoma |
| Q35880308 | Class selection of amino acid metabolites in body fluids using chemical derivatization and their enhanced 13C NMR. |
| Q37177549 | Clinical applications of metabolomics in oncology: a review |
| Q30647206 | Clustering Based on Periodicity in High-Throughput Time Course Data |
| Q36794155 | Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity |
| Q37366637 | Comparison of analytical mathematical approaches for identifying key nuclear magnetic resonance spectroscopy biomarkers in the diagnosis and assessment of clinical change of diseases |
| Q37402085 | Correlative and quantitative 1H NMR-based metabolomics reveals specific metabolic pathway disturbances in diabetic rats |
| Q37004712 | Critical evaluation of 1H NMR metabonomics of serum as a methodology for disease risk assessment and diagnostics |
| Q61718834 | Diagnosing diabetic nephropathy by 1H NMR metabonomics of serum |
| Q34783824 | Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe |
| Q34369288 | Early detection of recurrent breast cancer using metabolite profiling |
| Q37109550 | Early stage diagnosis of oral cancer using 1H NMR-based metabolomics |
| Q38389338 | Extracting biomarkers of commitment to cancer development: potential role of vibrational spectroscopy in systems biology |
| Q37738489 | Fingerprinting breast cancer vs. normal mammary cells by mass spectrometric analysis of volatiles |
| Q36816026 | Global metabolic profiling and its role in systems biology to advance personalized medicine in the 21st century |
| Q47150076 | High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism |
| Q35458562 | Human metabolic profiles are stably controlled by genetic and environmental variation |
| Q34142972 | Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform |
| Q28478197 | Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer |
| Q37643626 | Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors |
| Q41125108 | Identification of phosphatidylcholine and lysophosphatidylcholine as novel biomarkers for cervical cancers in a prospective cohort study |
| Q38799789 | Informatics for Metabolomics |
| Q42960221 | Interdependence of signal processing and analysis of urine 1H NMR spectra for metabolic profiling |
| Q64889177 | LC/MS-Based Polar Metabolite Profiling Identified Unique Biomarker Signatures for Cervical Cancer and Cervical Intraepithelial Neoplasia Using Global and Targeted Metabolomics. |
| Q35171890 | Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas |
| Q37213130 | Measurement of dietary exposure: a challenging problem which may be overcome thanks to metabolomics? |
| Q28469040 | Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia |
| Q37289506 | Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection |
| Q38920122 | Metabolic profiling of epithelial ovarian cancer cell lines: evaluation of harvesting protocols for profiling using NMR spectroscopy. |
| Q33255317 | Metabolic profiling of patients with schizophrenia |
| Q35844833 | Metabolic signatures differentiate ovarian from colon cancer cell lines |
| Q48445931 | Metabolomic Analysis Provides Insights on Paraquat-Induced Parkinson-Like Symptoms in Drosophila melanogaster. |
| Q37645012 | Metabolomic Analysis of Liver Tissue from the VX2 Rabbit Model of Secondary Liver Tumors |
| Q33844916 | Metabolomic Profiling of the Synergistic Effects of Melittin in Combination with Cisplatin on Ovarian Cancer Cells |
| Q37685038 | Metabolomic approach to human brain spectroscopy identifies associations between clinical features and the frontal lobe metabolome in multiple sclerosis. |
| Q50073593 | Metabolomic characterization of experimental ovarian cancer ascitic fluid. |
| Q34620002 | Metabolomic mapping of atypical antipsychotic effects in schizophrenia. |
| Q92105040 | Metabolomic prediction of endometrial cancer |
| Q57146844 | Metabolomic serum profiling detects early-stage high-grade serous ovarian cancer in a mouse model |
| Q36406413 | Metabolomic signature of brain cancer |
| Q38227841 | Metabolomic studies of human gastric cancer: review |
| Q37852648 | Metabolomics and surgical oncology: Potential role for small molecule biomarkers |
| Q38141081 | Metabolomics in paediatric oncology: a potential still to be exploited |
| Q38997162 | Metabolomics in pancreatic cancer biomarkers research |
| Q28829522 | Metabolomics in the assessment of chemical-induced reproductive and developmental outcomes using non-invasive biological fluids: application to the study of butylbenzyl phthalate |
| Q37867682 | Metabolomics in urogenital cancer |
| Q41403906 | Metabolomics of biomarker discovery in ovarian cancer: a systematic review of the current literature |
| Q47205404 | Metabolomics technology and bioinformatics for precision medicine. |
| Q37266489 | Metabolomics-based methods for early disease diagnostics |
| Q37289766 | Metabolomics: a global biochemical approach to the study of central nervous system diseases |
| Q37462435 | Metabolomics: moving to the clinic |
| Q34766684 | Metabonomic profiling of serum and urine by (1)H NMR-based spectroscopy discriminates patients with chronic obstructive pulmonary disease and healthy individuals |
| Q36224709 | Metabonomic signature analysis of cervical carcinoma and precancerous lesions in women by (1)H NMR spectroscopy |
| Q36735003 | Metabonomics in pharmaceutical R&D. |
| Q40232916 | Metabonomics study on the hot syndrome of traditional Chinese medicine by rapid resolution liquid chromatography combined with quadrupole time-of-flight tandem mass spectrometry |
| Q36484646 | Metabonomics techniques and applications to pharmaceutical research & development |
| Q36630002 | Monitoring the health to disease continuum with global metabolic profiling and systems biology |
| Q35734379 | NMR Metabolomics Analysis of Parkinson's Disease |
| Q34444673 | NMR and pattern recognition methods in metabolomics: from data acquisition to biomarker discovery: a review |
| Q92816460 | NMR-Based Metabolomics in Metal-Based Drug Research |
| Q37301856 | NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer |
| Q57016043 | NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations |
| Q59139134 | NMR-based metabolomics to select a surgical method for treating papillary thyroid carcinoma |
| Q37633731 | Neuroblastoma treatment in the post-genomic era. |
| Q48308467 | Novel serum metabolomics-based approach by gas chromatography/triple quadrupole mass spectrometry for detection of human skin cancers: Candidate biomarkers. |
| Q33495701 | Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines. |
| Q57180544 | Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism |
| Q92347062 | P-MAPA and IL-12 Differentially Regulate Proteins Associated with Ovarian Cancer Progression: A Proteomic Study |
| Q60916001 | PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers |
| Q36607286 | Pattern recognition and biomarker validation using quantitative 1H-NMR-based metabolomics |
| Q31147103 | Piecewise multivariate modelling of sequential metabolic profiling data |
| Q90481627 | Plasma metabolite profiling and chemometric analyses of tobacco snuff dippers and patients with oral cancer: Relationship between metabolic signatures |
| Q37272725 | Postgenomics diagnostics: metabolomics approaches to human blood profiling |
| Q37004622 | Potential role of body fluid 1H NMR metabonomics as a prognostic and diagnostic tool |
| Q36325835 | Progress in capillary electrophoresis of biomarkers and metabolites between 2002 and 2005. |
| Q47752038 | Progress toward the determination of correct classification rates in fire debris analysis II: utilizing soft independent modeling of class analogy (SIMCA). |
| Q57113420 | Protective Effects of Total Glycoside From Leaves on Diabetic Nephropathy Rats via Regulating the Metabolic Profiling and Modulating the TGF-β1 and Wnt/β-Catenin Signaling Pathway |
| Q34634997 | Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication |
| Q34595084 | Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease |
| Q36796169 | Qishen Yiqi Drop Pill improves cardiac function after myocardial ischemia |
| Q37981214 | Quantitative analysis in magnetic resonance spectroscopy: from metabolic profiling to in vivo biomarkers |
| Q37990967 | Recent advances in metabolomics in oncology |
| Q44792666 | Revealing the metabonomic variation of EC using ¹H-NMR spectroscopy and its association with the clinicopathological characteristics |
| Q51113701 | Saturated fatty acids as possible important metabolites for epithelial ovarian cancer based on the free and esterified fatty acid profiles determined by GC-MS analysis. |
| Q43187905 | Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. |
| Q37022332 | Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer |
| Q37810160 | Spectroscopic and statistical methods in metabonomics |
| Q35906724 | Targeted metabolomics |
| Q36761890 | Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment |
| Q36525175 | The application of NMR-based metabonomics in neurological disorders |
| Q37475152 | The impact of new research technologies on our understanding of environmental causes of disease: the concept of clinical vulnerability |
| Q37800811 | The role of metabolites and metabolomics in clinically applicable biomarkers of disease. |
| Q30792204 | The use of EEM fluorescence data and OPLS/UPLS-DA algorithm to discriminate between normal and cancer cell lines: a feasibility study |
| Q36493048 | Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials |
| Q37783850 | Understanding subfertility at a molecular level in the female through the application of nuclear magnetic resonance (NMR) spectroscopy |
| Q38012884 | Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy |
| Q49057114 | Urinary hydrophilic and hydrophobic metabolic profiling based on liquid chromatography-mass spectrometry methods: Differential metabolite discovery specific to ovarian cancer. |
| Q57556407 | Use of genome-wide high-throughput technologies in biomarker development |
| Q37374479 | Use of nuclear magnetic resonance-based metabolomics in detecting drug resistance in cancer |
| Q41935417 | Visualization of bile homeostasis using (1)H-NMR spectroscopy as a route for assessing liver cancer |
| Q55437268 | [Preliminary results of metabolite in serum and urine of lung cancer patients detected by metabolomics]. |
Search more.